Follow
Rene Bruno
Rene Bruno
Genentech/Roche
Verified email at roche.com
Title
Cited by
Cited by
Year
Population pharmacokinetics/pharmacodynamics of docetaxel in phase II studies in patients with cancer.
R Bruno, D Hille, A Riva, N Vivier, WW ten Bokkel Huinnink, ...
Journal of clinical oncology 16 (1), 187-196, 1998
4891998
Clinical pharmacokinetics of bevacizumab in patients with solid tumors
JF Lu, R Bruno, S Eppler, W Novotny, B Lum, J Gaudreault
Cancer chemotherapy and pharmacology 62, 779-786, 2008
3942008
A population pharmacokinetic model for docetaxel (Taxotere®): Model building and validation
R Bruno, N Vivier, JC Vergniol, SL De Phillips, G Montay, LB Sheiner
Journal of pharmacokinetics and biopharmaceutics 24, 153-172, 1996
3331996
Phase I and pharmacokinetic study of Taxotere (RP 56976; NSC 628503) given as a short intravenous infusion
JM Extra, F Rousseau, R Bruno, M Clavel, NL Bail, M Marty
Cancer research 53 (5), 1037-1042, 1993
3261993
Model-based prediction of phase III overall survival in colorectal cancer on the basis of phase II tumor dynamics
L Claret, P Girard, PM Hoff, E Van Cutsem, KP Zuideveld, K Jorga, ...
Journal of Clinical Oncology 27 (25), 4103-4108, 2009
3202009
Population pharmacokinetics of trastuzumab in patients with HER2+ metastatic breast cancer
R Bruno, CB Washington, JF Lu, G Lieberman, L Banken, P Klein
Cancer chemotherapy and pharmacology 56, 361-369, 2005
2882005
Clinical pharmacokinetics of erlotinib in patients with solid tumors and exposure‐safety relationship in patients with non–small cell lung cancer
JF Lu, SM Eppler, J Wolf, M Hamilton, A Rakhit, R Bruno, BL Lum
Clinical Pharmacology & Therapeutics 80 (2), 136-145, 2006
2522006
The effect of an individual’s cytochrome CYP3A4 activity on docetaxel clearance
JA Hirth, PB Watkins, M Strawderman, A Schott, R Bruno, LH Baker
Clinical cancer research 6 (4), 1255-1258, 2000
2442000
Population pharmacokinetics of rituximab (anti‐CD20 monoclonal antibody) in rheumatoid arthritis patients during a phase II clinical trial
CM Ng, R Bruno, D Combs, B Davies
The Journal of Clinical Pharmacology 45 (7), 792-801, 2005
2212005
Phase II and pharmacologic study of docetaxel as initial chemotherapy for metastatic breast cancer
CA Hudis, AD Seidman, JPA Crown, C Balmaceda, R Freilich, ...
Journal of clinical oncology 14 (1), 58-65, 1996
1781996
Evaluation of tumor-size response metrics to predict overall survival in Western and Chinese patients with first-line metastatic colorectal cancer
L Claret, M Gupta, K Han, A Joshi, N Sarapa, J He, B Powell, R Bruno
Journal of Clinical Oncology 31 (17), 2110-2114, 2013
1502013
Tinzaparin and enoxaparin given at prophylactic dose for eight days in medical elderly patients with impaired renal function
I Mahé, M Aghassarian, L Drouet, K Lacut, JJ Heilmann, D Mottier, ...
Thrombosis and haemostasis 97 (04), 581-586, 2007
1472007
Population pharmacokinetics and pharmacokinetic-pharmacodynamic relationships for docetaxel
R Bruno, N Vivier, C Veyrat-Follet, G Montay, GR Rhodes
Investigational new drugs 19, 163-169, 2001
1412001
Clinical pharmacokinetics and pharmacodynamics of atezolizumab in metastatic urothelial carcinoma
M Stroh, H Winter, M Marchand, L Claret, S Eppler, J Ruppel, O Abidoye, ...
Clinical Pharmacology & Therapeutics 102 (2), 305-312, 2017
1282017
Determination of Taxotere in human plasma by a semi-automated high-performance liquid chromatographic method
JC Vergniol, R Bruno, G Montay, A Frydman
Journal of Chromatography B: Biomedical Sciences and Applications 582 (1-2 …, 1992
1221992
Fisher information matrix for non‐linear mixed‐effects models: evaluation and application for optimal design of enoxaparin population pharmacokinetics
S Retout, F Mentré, R Bruno
Statistics in medicine 21 (18), 2623-2639, 2002
1212002
Fixed dosing of HER antibodies
DE Allison, R Bruno, JF Lu, CM Ng
US Patent 7,449,184, 2008
116*2008
α-1-Acid glycoprotein as an independent predictor for treatment effects and a prognostic factor of survival in patients with non-small cell lung cancer treated with docetaxel
R Bruno, R Olivares, J Berille, P Chaikin, N Vivier, L Hammershaimb, ...
Clinical cancer research 9 (3), 1077-1082, 2003
1152003
Pharmacokinetics and metabolism of Taxotere (docetaxel).
R Bruno, GJ Sanderink
Cancer surveys 17, 305-313, 1993
1101993
Phase I trial of docetaxel and cisplatin in previously untreated patients with advanced non-small-cell lung cancer.
MJ Millward, J Zalcberg, JF Bishop, LK Webster, A Zimet, D Rischin, ...
Journal of clinical oncology 15 (2), 750-758, 1997
1071997
The system can't perform the operation now. Try again later.
Articles 1–20